New drug may offer better control for rare Muscle-Weakening disease before surgery

NCT ID NCT07231523

Not yet recruiting Disease control Sponsor: Shanghai Zhongshan Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a newer drug, efgartigimod, works better than standard intravenous immunoglobulin (IVIG) for people with myasthenia gravis who also have a thymoma tumor and need surgery. About 64 adults will receive either treatment before and after their operation to see which one improves muscle strength and daily activities more. The goal is to find a safer, more effective option to manage symptoms during this critical time.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EFGARTIGIMOD are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myasthenia gravis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

EFGARTIGIMOD INTRAVENOUS IMMUNOGLOBULIN MYASTHENIA GRAVIS ASSOCIATED WITH THYMOMA

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Shanghai Zhongshan Hospital

Shanghai, Shanghai Municipality, 200032, China

Contact Phone: •••-•••-•••• Email: •••••@•••••